title: [Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma].
abstract: A 62-year-old Japanese woman was diagnosed as having follicular lymphoma (FL, grade 3, CS IIIA, IPI high-intermediate risk) in May 1998. After eight courses of CHOP therapy, she achieved a complete remission (CR). In November 1998, her FL relapsed, and she achieved a second CR after two courses of MINE therapy. High-dose etoposide was used for autologous peripheral stem cell mobilization. In May 1999, she underwent high-dose chemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT). Four months after the auto-PBSCT, bilateral cervical lymphadenopathy developed. Histopathological findings from a biopsied cervical lymph node showed angioimmunoblastic T-cell lymphoma (AILT). The patient was treated with modified CVP therapy, and she is alive with no evidence of lymphoma five years after auto-PBSCT. Clinical and histopathological findings showed that the FL and AILT in this case were not concomitant. It is thought that in this case, the AILT developed as a post-transplant lymphoproliferative disorder after auto-PBSCT for the FL.
authors.affiliation: Second Department of Internal Medicine, Mie University School of Medicine.
authors.forename: Kana
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Masuya
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Isaka
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakase
authors.forename: Tohru
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy / Q000209:etiology*; D008224:Lymphoma, Follicular / Q000150:complications / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000209:etiology*; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D011241:Prednisone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011241:Prednisone